Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...

La La Anthony is partnering with Amgen to raise awareness and support those struggling with plaque psoriasis. The ...

Amgen announces the launch of Amgen India, a new technology and innovation hub in Hyderabad, that spans approximately 524,000 ...

Amgen (NASDAQ: AMGN) will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner, executive vice president of Research and Development at ...

Amgen opens new technology and innovation site in Hyderabad, to invest $200 million through 2025: Our Bureau, Bengaluru ...